Roche's KRAS inhibitor divarasib shows strong results in second-line lung cancer trial at ESMO

Roche presented data from a trial of its KRAS G12C inhibitor divarasib at the European Society for Medical Oncology meeting.

The study evaluated divarasib in patients with advanced non-small cell lung cancer who had received prior therapy, focusing on the second-line setting.

Results showed a notable response rate and disease control, which the authors described as one of the more impressive data sets at the conference.

If confirmed, the findings could place divarasib in a leading position among KRAS-targeted therapies for lung cancer.